TMS as a Translational Tool to Bridge Pathophysiology to Novel Interventions in Autism Spectrum Disorder

Presenting: TMS as a Translational Tool to Bridge Pathophysiology to Novel Interventions in Autism Spectrum Disorder

You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
TMS as a Translational Tool to Bridge Pathophysiology to Novel Interventions in Autism Spectrum Disorder

Learning objectives: 

1.     Review the findings of studies using TMS to probe the mechanisms of intracortical inhibition and plasticity in autism spectrum disorder (ASD).

2.     Describe how TMS can be used to induce long-term changes in brain network functioning and potentially treat core and associated symptoms of ASD and related disorders.

3.     Identify a number of potential network targets where applying TMS may be effective for reducing specific targeted symptom domains.

Date & Time: Tuesday, May 7, 2019 | 5:00 PM (PDT) - 6:00 PM (PDT)

Format: On-Demand

Cost: Members: $25 | Non-members $50 | Student Members FREE

Speakers: Dr. Lindsay Oberman, PhD
 

Dr. Lindsay Oberman, PhD is the Clinical Program Leader for TMS trials at the Center for Neuroscience and Regenerative Medicine with a faculty appointment in the Department of Medical and Clinical Psychology at the Uniformed Services University (USU).  She is also a “Special Volunteer” in the Noninvasive Neuromodulation Unit, National Institute of Mental Health, National Institutes of Health.  The focus of her research is to investigate the mechanisms that contribute to the function and dysfunction of neural systems involved in the core symptoms of complex neuropsychiatric disorders with the ultimate goal of developing novel treatment strategies.  Over the past 16 years working in this field, she has gained an appreciation for the complexity of the pathophysiology of behaviorally defined disorders. Thus, she has recently shifted her focus to identifying and modifying neural circuits associated with specific cross diagnostic behavioral domains (such as mood regulation, sensory processing, social cognition, language processing, and executive functioning/cognitive control) in order to better target the symptoms that affect the quality of life of individuals with neuropsychiatric and neurodevelopmental disorders including autism spectrum disorder, traumatic brain injury, and post-traumatic stress disorder.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.